Characterizing Late-season Influenza Vaccine Responses to Compare the 2023 and 2024 Vaccine Formulations

NCT06567860 · clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
23
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

La Jolla Institute for Immunology